New driver mutations in non-small-cell lung cancer
William J. Pao, Nicolas Girard · The Lancet Oncology · 2011
Cited by 1,128 works. doi:10.1016/s1470-2045(10)70087-5
Authors
References
- Mutations of the BRAF gene in human cancer
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Somatic mutations affect key pathways in lung adenocarcinoma
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- Activation of the MAP kinase pathway by the protein kinase raf